These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26045239)

  • 1. Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis.
    Wan KH; Chen LJ; Young AL
    Ocul Surf; 2015 Jul; 13(3):213-25. PubMed ID: 26045239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis.
    Zhou XQ; Wei RL
    Cornea; 2014 Jul; 33(7):760-7. PubMed ID: 24815112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
    Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
    Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
    Kim EC; Choi JS; Joo CK
    Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
    Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
    Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
    Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M
    Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
    Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
    Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
    Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
    Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of Langerhans Cells in the Central Cornea as Tool for Monitoring Inflammatory Changes in Patients with Keratoconjunctivitis sicca under Topical Therapy with Cyclosporine A 0.05% Eye Drops].
    Schneider E; Paulsen F; Jacobi C
    Klin Monbl Augenheilkd; 2020 May; 237(5):669-674. PubMed ID: 32434251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.